T22-HSNBT-MMAE

N/A

Report date: 2025/06/11 10:16:11

Base Information

Drug NameT22-HSNBT-MMAE
Drug Alias NameMMAE-based CXCR4-targeted peptide nanconjugate (Nanoligent)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionC-X-C motif chemokine receptor 4 antagonistsCell cycle inhibitors
TargetsC-X-C motif chemokine receptor 4
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversitat Autonoma De Barcelona
China Registration ClassN/A

Develop Information

Active CompaniesNanoligent SL
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A